208 related articles for article (PubMed ID: 30741815)
21. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
[TBL] [Abstract][Full Text] [Related]
22. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis.
Pergialiotis V; Bellos I; Hatziagelaki E; Antsaklis A; Loutradis D; Daskalakis G
Am J Obstet Gynecol; 2019 Nov; 221(5):429-436.e5. PubMed ID: 31132340
[TBL] [Abstract][Full Text] [Related]
23. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
24. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
Shaamash AH; Ali MK; Attyia KM
J Obstet Gynaecol; 2020 Jul; 40(5):633-638. PubMed ID: 31670998
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
26. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
[TBL] [Abstract][Full Text] [Related]
27. The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17α-hydroxyprogesterone caproate.
Wolfe K; Dearmond C; How H; Henderson ZT; Sibai B
Am J Perinatol; 2011 Dec; 28(10):741-6. PubMed ID: 21660898
[TBL] [Abstract][Full Text] [Related]
28. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
[TBL] [Abstract][Full Text] [Related]
29. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
Rebarber A; Istwan NB; Russo-Stieglitz K; Cleary-Goldman J; Rhea DJ; Stanziano GJ; Saltzman DH
Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346
[TBL] [Abstract][Full Text] [Related]
30. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Sanchez-Ramos L; Kaunitz AM; Delke I
Obstet Gynecol; 2005 Feb; 105(2):273-9. PubMed ID: 15684151
[TBL] [Abstract][Full Text] [Related]
31. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
[TBL] [Abstract][Full Text] [Related]
32. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
[TBL] [Abstract][Full Text] [Related]
33. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
[TBL] [Abstract][Full Text] [Related]
34. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
35. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
Ward A; Greenberg V; Valcarcel B; Boelig RC; Al-Kouatly HB; Berghella V
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870
[TBL] [Abstract][Full Text] [Related]
36. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
37. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Saha PT; Mbewe FM; Phiri WM; Peterson M; Muyangwa D; Sindano N; Mwape H; Smithmyer ME; Kasaro MP; Rouse DJ; Goldenberg RL; Chomba E; Stringer JSA
Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Oler E; Eke AC; Hesson A
Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
[TBL] [Abstract][Full Text] [Related]
39. Effects of progestogens in women with preterm premature rupture of membranes.
Di Sarno R; Raffone A; Saccone G
Minerva Ginecol; 2019 Apr; 71(2):121-124. PubMed ID: 30318880
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
